Eidos Therapeutics IncEIDX

A clinical-stage biopharmaceutical company developing a novel oral therapy for transthyretin amyloidosis, a rare and progressive protein misfolding disease. Its lead candidate, acoramidis, targets the underlying cause of the condition and has shown promising late-stage trial results. Investors track the company for its potential to capture a significant share of the growing ATTR amyloidosis treatment market.